Novo Nordisk (CPSE:NOVO B) Warns Europe Is Losing Pharma Competitiveness

• On 24 September 2026, European pharmaceutical groups including Novo Nordisk (CPSE:NOVO B) issued a joint warning on Europe's competitiveness.
• The companies cited rising research and development costs and growing market access hurdles as key pressures on European drug makers.
• The joint statement called for faster regulatory processes and stronger investment support from European policymakers.
• There is more to Novo Nordisk's outlook than this joint warning on Europe's pharmaceutical competitiveness. We have also spotted 2 warning signs (1 major) worth knowing about at Novo Nordisk.

Consider broadening your watchlist to other major drug makers in Europe and beyond by exploring 174 high quality undervalued stocks.

Novo Nordisk, a pharmaceuticals heavyweight with a market value of about DKK1.1 trillion, depends on large scale research and distribution of treatments, so any shift in European rules or funding directly affects how quickly its therapies can reach patients and generate returns on those projects.

3 things going right for Novo Nordisk that this headline doesn't cover.

How does this Europe pharma warning intersect with Novo Nordisk's current pipeline moves?

For Novo Nordisk, the warning lands just as it reports phase 3 CagriSema results, positive CHMP opinions for FREHEMGO and Sogroya, and fresh collaborations with Siemens Healthineers, Orbis Medicines and Anthropic. The tension is clear. The group is adding potential new revenue streams in obesity, rare disease, liver and cardiometabolic care while arguing that European rules and funding could still slow access and payback on those projects.

Does this change the Novo Nordisk Narrative investors have been using?

The Narrative already flags a push to broaden GLP 1 anchored obesity and diabetes earnings into adjacent areas such as MASH, rare disease and cardiovascular care. This is supported by heavy R&D and manufacturing spend and set against risks from pricing pressure, generics and rising costs. This competitiveness warning leans into that risk side, because if European price erosion or delayed reimbursement deepen, it makes the margin compression and slower volume concerns in the Narrative more pressing even as global GLP 1 demand remains underpenetrated.

See how these catalysts shape Novo Nordisk's path to a DKK310 fair value.

What should you watch next to judge whether this warning really bites for Novo Nordisk?

The most concrete gauges will be European decisions through late 2026 on products already in motion. Investors can watch how quickly the European Commission converts CHMP opinions on FREHEMGO and Sogroya into approvals and real world launches, and whether pricing and reimbursement terms for Wegovy, Ozempic and upcoming CagriSema in Europe look tighter or more supportive compared with recent periods.

The one Novo Nordisk check to run before acting on today’s headlines

Short term stories only tell you where Novo Nordisk is now. The real question is where analysts expect the business to be several years from here. See where analysts expect Novo Nordisk to be in a few years.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com